-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The pharmaceutical manufacturing industry refers to the process in which raw materials become new pharmaceutical products after physical or chemical changes, including the manufacturing of Chinese and Western medicines, veterinary medicines, raw medicines and sanitary materials
.
The pharmaceutical manufacturing industry has always been an important part of the national economy and is closely related to the vital interests of the people's life, health and quality of life
.
It is worth noting that in recent years, driven by a series of medical reform policies, while the development of China's pharmaceutical manufacturing industry has been further accelerated, the scale has also begun to expand
.
China’s pharmaceutical manufacturing industry has ushered in a “golden development period” (picture source: Pharmaceutical Network) According to the National Bureau of Statistics, the operating income of China’s pharmaceutical manufacturing industry above designated size has continued to grow from 2015 to 2020, and this value has reached 2.
49 trillion yuan in 2020.
The growth rate is about 4.
5%, which is 2.
2 percentage points higher than China's GDP growth rate (2.
3%) in 2020
.
Analysts believe that under the background that patents for original research drugs with sales of close to US$252 billion in sales from 2021 to 2026 are about to expire, Chinese pharmaceutical companies will also usher in huge development opportunities
.
Affected by this, China's pharmaceutical manufacturing industry will also usher in more benefits, and operating income may reach new highs
.
According to the preliminary estimates of the Qianzhan Industry Research Institute, by 2026, the operating income of China's pharmaceutical manufacturing enterprises above designated size may reach 3.
17 trillion yuan
.
Of course, in addition to huge opportunities for pharmaceutical manufacturing companies, the industry has proposed that the pharmaceutical machinery industry is also expected to fully benefit
.
It is understood that since 2021, with the intensive release of favorable policies, both the growth rate of fixed asset investment and corporate profits in the domestic manufacturing industry have improved, and the trend is improving
.
Statistics show that manufacturing investment from January to August has increased by 15.
7% year-on-year
.
We must know that the pharmaceutical equipment industry has always been an important part of the manufacturing industry.
With the continuous improvement of the manufacturing industry, the pharmaceutical equipment industry as a sub-industry will naturally usher in more new opportunities
.
In fact, since the beginning of this year, with the development of the pharmaceutical manufacturing industry improving, a large number of pharmaceutical equipment companies have shown a trend of booming production and sales, full orders, and stable production and operation.
.
For example, the performance forecast issued by Dong Fulong on July 6 shows that the net profit attributable to shareholders of listed companies in the first half of 2021 is expected to reach approximately 310 million to 344 million yuan
.
It should be noted that despite policy support, increased investment, and the continued improvement of the pharmaceutical environment, the pharmaceutical equipment industry will usher in opportunities
.
But how to seize the opportunity is actually becoming an urgent problem for pharmaceutical companies to solve
.
In this regard, industry insiders believe that from the current national and local policies to promote industrial development, intelligence, digitalization, and greening will be the new requirements for the high-quality development of the entire manufacturing industry; this is also true for the pharmaceutical equipment industry.
Pharmaceutical machinery companies will have a lot to do
.
According to the author's understanding, in fact, the current development trend and transformation and upgrading of China's pharmaceutical equipment industry have begun to accelerate their development in the direction of digitization, informatization, intelligent and green
.
Among them, the deployment of automation and intelligence has become a major change in the development of the industry
.
It is reported that this is mainly due to the fact that many domestic policies are vigorously supporting the development of intelligent manufacturing
.
For example, "Made in China 2025" proposes to accelerate the development of the integration of a new generation of information technology and manufacturing technology, take intelligent manufacturing as the main direction of the in-depth integration of the two, and promote the transformation of China's manufacturing model from "Made in China" to "Intelligent Manufacturing in China
.
" The "Fourteenth Five-Year Plan for Intelligent Manufacturing Development" (draft for comments) also clearly stated that by 2025, manufacturing enterprises above designated size will be basically digitized, and key industries in key industries will initially achieve intelligent transformation
.
On the whole, at the moment when the pharmaceutical manufacturing industry is developing well, it has become a consensus that the pharmaceutical equipment industry is ushering in a period of opportunity
.
In the future, both the growth rate of fixed asset investment and the development of enterprises will continue to improve
.
However, the industry also emphasizes that there are still many shortcomings in the current development of the pharmaceutical equipment industry, such as the lack of innovation in the development of digitization, networking, and intelligence, and the level of information technology application is still in the primary or partial application stage.
.
Therefore, relevant companies still need to continue to improve the level of digitalization and intelligence of their products through innovation, and expand beyond the high-end market; they also need to explore more new supporting technologies and device applications based on actual conditions to continue to meet customer needs.
Demand
.
.
The pharmaceutical manufacturing industry has always been an important part of the national economy and is closely related to the vital interests of the people's life, health and quality of life
.
It is worth noting that in recent years, driven by a series of medical reform policies, while the development of China's pharmaceutical manufacturing industry has been further accelerated, the scale has also begun to expand
.
China’s pharmaceutical manufacturing industry has ushered in a “golden development period” (picture source: Pharmaceutical Network) According to the National Bureau of Statistics, the operating income of China’s pharmaceutical manufacturing industry above designated size has continued to grow from 2015 to 2020, and this value has reached 2.
49 trillion yuan in 2020.
The growth rate is about 4.
5%, which is 2.
2 percentage points higher than China's GDP growth rate (2.
3%) in 2020
.
Analysts believe that under the background that patents for original research drugs with sales of close to US$252 billion in sales from 2021 to 2026 are about to expire, Chinese pharmaceutical companies will also usher in huge development opportunities
.
Affected by this, China's pharmaceutical manufacturing industry will also usher in more benefits, and operating income may reach new highs
.
According to the preliminary estimates of the Qianzhan Industry Research Institute, by 2026, the operating income of China's pharmaceutical manufacturing enterprises above designated size may reach 3.
17 trillion yuan
.
Of course, in addition to huge opportunities for pharmaceutical manufacturing companies, the industry has proposed that the pharmaceutical machinery industry is also expected to fully benefit
.
It is understood that since 2021, with the intensive release of favorable policies, both the growth rate of fixed asset investment and corporate profits in the domestic manufacturing industry have improved, and the trend is improving
.
Statistics show that manufacturing investment from January to August has increased by 15.
7% year-on-year
.
We must know that the pharmaceutical equipment industry has always been an important part of the manufacturing industry.
With the continuous improvement of the manufacturing industry, the pharmaceutical equipment industry as a sub-industry will naturally usher in more new opportunities
.
In fact, since the beginning of this year, with the development of the pharmaceutical manufacturing industry improving, a large number of pharmaceutical equipment companies have shown a trend of booming production and sales, full orders, and stable production and operation.
.
For example, the performance forecast issued by Dong Fulong on July 6 shows that the net profit attributable to shareholders of listed companies in the first half of 2021 is expected to reach approximately 310 million to 344 million yuan
.
It should be noted that despite policy support, increased investment, and the continued improvement of the pharmaceutical environment, the pharmaceutical equipment industry will usher in opportunities
.
But how to seize the opportunity is actually becoming an urgent problem for pharmaceutical companies to solve
.
In this regard, industry insiders believe that from the current national and local policies to promote industrial development, intelligence, digitalization, and greening will be the new requirements for the high-quality development of the entire manufacturing industry; this is also true for the pharmaceutical equipment industry.
Pharmaceutical machinery companies will have a lot to do
.
According to the author's understanding, in fact, the current development trend and transformation and upgrading of China's pharmaceutical equipment industry have begun to accelerate their development in the direction of digitization, informatization, intelligent and green
.
Among them, the deployment of automation and intelligence has become a major change in the development of the industry
.
It is reported that this is mainly due to the fact that many domestic policies are vigorously supporting the development of intelligent manufacturing
.
For example, "Made in China 2025" proposes to accelerate the development of the integration of a new generation of information technology and manufacturing technology, take intelligent manufacturing as the main direction of the in-depth integration of the two, and promote the transformation of China's manufacturing model from "Made in China" to "Intelligent Manufacturing in China
.
" The "Fourteenth Five-Year Plan for Intelligent Manufacturing Development" (draft for comments) also clearly stated that by 2025, manufacturing enterprises above designated size will be basically digitized, and key industries in key industries will initially achieve intelligent transformation
.
On the whole, at the moment when the pharmaceutical manufacturing industry is developing well, it has become a consensus that the pharmaceutical equipment industry is ushering in a period of opportunity
.
In the future, both the growth rate of fixed asset investment and the development of enterprises will continue to improve
.
However, the industry also emphasizes that there are still many shortcomings in the current development of the pharmaceutical equipment industry, such as the lack of innovation in the development of digitization, networking, and intelligence, and the level of information technology application is still in the primary or partial application stage.
.
Therefore, relevant companies still need to continue to improve the level of digitalization and intelligence of their products through innovation, and expand beyond the high-end market; they also need to explore more new supporting technologies and device applications based on actual conditions to continue to meet customer needs.
Demand
.
